此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

VR瞳孔测量在认知障碍中的应用

2026年11月8日 更新者:Victor Spoormaker、Max-Planck-Institute of Psychiatry

AD、MCI及抑郁相关认知障碍中的任务诱发瞳孔测量

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 6, 12 and 18 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

研究概览

详细说明

Cognitive performance typically declines with age and is usually accompanied by attention and memory deficits. While such changes can be consistent with normal ageing, they may also reflect affective disorders or early stages of neurodegenerative diseases (e.g. Alzheimer's Disease; AD). In clinical practice, neurocognitive tests are commonly used to distinguish age-appropriate change from pathological decline. As these tests quantify behavioral performance, they are better at detecting cognitive decline, once measurable deficits are manifested. However, they have limited sensitivity to subtle changes that can precede overt clinical symptoms by several years. This study evaluates a diagnostic approach based on pupil dilation measurements that may support earlier detection and longitudinal monitoring, potentially enabling earlier interventions.

Pupillometry provides a noninvasive index of pupil dynamics linked to arousal systems relevant to cognition, including the locus coeruleus-noradrenergic (LC-NA) system. LC-NA activity is coupled to pupil dilation via autonomic pathways, and this coupling has been demonstrated across animal and human studies. Given its widespread projections, the LC-NA system is implicated in psychiatric and neurological conditions through roles in arousal regulation, stress responsivity, attention, and memory. Pupillometry in Alzheimer's disease has often been examined using pupillary light reflex paradigms. However, simple light-flash measures may be less informative in early-stage impairment because pupil responses vary with cognitive state and task demands and do not provide a uniform, task-independent readout of LC-linked function. Accordingly, analyzing pupil responses during and immediately following cognitive tasks may be better suited to capturing subtle dysfunction relevant to prodromal processes, with light-reflex alterations potentially becoming more apparent once impairment is established. In prior work, the investigators observed pupil diameter increased with working-memory load during an N-back task. Most participants showed the expected increase in pupil dilation with task difficulty, whereas a subset exhibited pronounced atypical pupil responses despite only slight differences on standard neurocognitive measures. Building on these principles, this study uses a VR-based assessment to examine adults presenting with early, non-specific cognitive complaints. By systematically recording pupil dynamics during and following cognitive paradigms, the investigators aim to obtain readouts of LC-NA system function that may support differential diagnosis among conditions with overlapping clinical presentations (e.g. depression-related cognitive impairment vs. early dementia).

At each visit, participants are fitted with a VR headset by trained study personnel and complete VR-based assessments with concurrent eye tracking and behavioral performance recording. Assessments are conducted at baseline (T0) and repeated after 6 months (T1), 12 (T2) and 18 months (T3). At each visit, pupil responses and task performance are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Participants also complete routine neuropsychological testing, including the Montreal Cognitive Assessment (MoCA) and the CERAD battery comprising semantic fluency, Boston Naming Test, Mini-Mental State Examination (MMSE), word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. Additional assessments include the Bayer Activities of Daily Living scale (Bayer-ADL) and the Geriatric Depression Scale (GDS), as well as questionnaires assessing subjective cognitive impairment (FLei) and childhood adversity (CTQ). Sociodemographic data are recorded, including age, sex, education (years of schooling), and occupation. Blood is collected for routine laboratory measures and blood-based biomarker analyses (including phosphorylated tau 217), and clinical data from routine care are linked where available. In some cases, cerebrospinal fluid biomarkers from routine clinical evaluation are available and linked, including AD pathology markers (amyloid-β and tau measures).

Pupillometric and behavioral measures will be compared across cohorts and evaluated longitudinally across follow-up visits. Measures will also be related to routine neuropsychological assessment, as well as available clinical biomarkers (CSF amyloid-β and tau measures blood-based biomarkers and anatomical neuroimaging sequences). Prior observations suggest that pupil dilation scales with cognitive load and that task-evoked pupil responses can differ, even when standard neurocognitive measures show only subtle differences. The investigators hypothesize that task-evoked pupil response patterns will differ between cohorts and may be sensitive to change over time.

研究类型

观察性的

注册 (估计的)

140

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Bavaria
      • München、Bavaria、德国、80804
        • 招聘中
        • Max Planck Institute of Psychiatry
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adults aged 18-80 years will be recruited at the Max Planck Institute of Psychiatry (Munich, Germany) from inpatient wards and outpatient clinics. Patients have a suspected or confirmed clinical diagnosis of Alzheimer's disease, mild cognitive impairment, or depressive disorder with cognitive impairment. Routine clinical measures (neuropsychological testing and, CSF biomarkers, blood biomarkers, imaging) will be linked to study pupillometry outcomes.

描述

Inclusion Criteria:

  1. Written informed consent.
  2. Age 18-80 years.
  3. Ability to read and understand German.
  4. For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.

Exclusion Criteria:

  1. Acute suicidality (e.g. BDI suicidality item > 1).
  2. Change of psychotropic medication within the last 4 weeks.
  3. Lifetime psychotic disorder (ICD-10 F20-29).
  4. Lack of capacity to consent.
  5. Lifetime bipolar disorder (ICD-10 F31).
  6. Acute substance abuse or harmful use of alcohol or other psychoactive substances.
  7. Parkinson's syndrome (ICD-10 G20).
  8. Multiple sclerosis (ICD-10 G35).
  9. Stroke within the last 12 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Alzheimer's Disease

Participants with complaints of cognitive deficits and a diagnosis of Alzheimer's disease (AD) supported by cerebrospinal fluid (CSF) biomarker profile, where available.

Mild Cognitive Impairment without Alzheimer's Disease

Participants with complaints of cognitive deficits meeting criteria for mild cognitive impairment without evidence of Alzheimer's disease (CSF biomarkers not consistent with AD).

Depressive Disorder With Cognitive Impairment

Participants with complaints of cognitive impairment and no evidence of Alzheimer's pathology; deficits most consistent with depressive disorder.

Healthy Controls

Age-matched healthy volunteers.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Task-evoked pupil dilation during N-Back
大体时间:Baseline

Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

Baseline

次要结果测量

结果测量
措施说明
大体时间
Resting-state pupil dynamics
大体时间:Baseline, 6, 12 and 18 months.

Mean and variability of pupil diameter during resting fixation.

Baseline, 6, 12 and 18 months.
Reward-task pupil response
大体时间:Baseline, 6, 12 and 18 months.

Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during each condition (reward, control).

Baseline, 6, 12 and 18 months.
N-back behavioral performance
大体时间:Baseline, 6, 12 and 18 months.

Behavioral performance during the VR N-back task, quantified as accuracy and reaction time for each load condition ( 0-, 1-, 2-back).

Baseline, 6, 12 and 18 months.
Montreal Cognitive Assessment (MoCA)
大体时间:Baseline, 6, 12 and 18 months.

Global cognitive screening tool used to quantify overall cognitive impairment. Range: 0-30; higher scores indicate better cognitive performance.

Baseline, 6, 12 and 18 months.
CERAD cognitive battery (CERAD-Plus), norm-referenced z-scores
大体时间:Baseline, 6, 12 and 18 months.

CERAD-Plus subtests include semantic fluency, Boston Naming Test, word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. The subtests will be evaluated using age-/education-adjusted norm-referenced z-scores. A z-score of 0 corresponds to the normative mean; higher z-scores indicate better cognitive performance and lower z-scores indicate worse performance.

Baseline, 6, 12 and 18 months.
Bayer Activities of Daily Living (Bayer-ADL)
大体时间:Baseline, 6, 12 and 18 months.

Functional status measured using the Bayer-ADL mean item score (quotient). Range: 1.00-10.00. Higher scores indicate worse functional impairment (more difficulty with activities of daily living).

Baseline, 6, 12 and 18 months.
Geriatric Depression Scale
大体时间:Baseline, 6, 12 and 18 months.

Geriatric Depression Scale, 30-item version (GDS-30), total score (depressive symptoms). Range: 0-30; higher scores indicate more depressive symptoms.

Baseline, 6, 12 and 18 months.
Subjective cognitive impairment (Fragebogen zur geistigen Leistungsfähigkeit; FLei), total score
大体时间:Baseline, 6, 12 and 18 months.

35-item self-report assessing cognitive difficulties over the last 6 months (0-4 per item). Range: 0-140. Higher scores indicate greater subjective cognitive impairment (more perceived difficulties).

Baseline, 6, 12 and 18 months.
Childhood Trauma Questionnaire (CTQ)
大体时间:Baseline.

Retrospective recall-based measures administered to adults. Used to determine experiences of childhood trauma. Higher scores indicate greater childhood adversity.

Baseline.
Blood-based biomarkers
大体时间:Baseline, 6, 12 and 18 months.

Blood biomarker concentrations assessed from collected blood samples, including phosphorylated tau 217 (p-tau217) and Aβ1-42/Aβ1-40 ratio.

Baseline, 6, 12 and 18 months.
CSF Alzheimer's disease pathology markers
大体时间:Baseline.

CSF biomarkers from routine clinical evaluation where available, including Aβ1-42, Aβ1-40, Aβ1-42/Aβ1-40 ratio, total tau, and phosphorylated tau.

Baseline.
Task-evoked pupil dilation during N-Back
大体时间:Baseline, 6, 12 and 18 months.

Pupil response metrics (mean relative pupil diameter in each condition; load-dependent slope across conditions) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

Baseline, 6, 12 and 18 months.

其他结果措施

结果测量
措施说明
大体时间
Between-group differences in N-back pupil metrics
大体时间:Baseline, 6, 12 and 18 months.

Comparison of the primary N-back pupil load metric across the four cohorts (Alzheimer's disease, mild cognitive impairment, depressive disorder with cognitive impairment, healthy controls).

Baseline, 6, 12 and 18 months.
Association between task-evoked pupil responses and cognitive test performance
大体时间:Baseline, 6, 12 and 18 months.

Association between the N-back pupil metrics and cognitive performance measures (MoCA total score; CERAD-Plus subtest z-scores).

Baseline, 6, 12 and 18 months.
Association between task-evoked pupil responses and AD pathology markers
大体时间:Baseline through 18 months, using biomarker time points available

Association between the N-back pupil metrics and available biomarkers of AD pathology (CSF and blood-based biomarkers).

Baseline through 18 months, using biomarker time points available
Change from baseline in N-back pupil metrics
大体时间:Baseline, 6, 12 and 18 months.

Within-participant change from baseline in the prespecified N-back pupil load metric

Baseline, 6, 12 and 18 months.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Victor I. Spoormaker, PhD、Max-Planck-Institute of Psychiatry

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年1月12日

首先提交符合 QC 标准的

2026年2月3日

首次发布 (实际的)

2026年2月11日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月8日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅